Literature DB >> 30649610

Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review.

Jay K Ferrell1, Jess C Mace2, Daniel Clayburgh2.   

Abstract

PURPOSE: Salivary gland carcinomas (SGC) are rare malignancies and data regarding treatment outcomes stratified by histologic subtype are currently limited. This study aims to examine current, national treatment patterns and overall survival (OS) of patients with the major histologic subtypes of salivary gland carcinoma. SUBJECTS AND METHODS: A review was performed of the National Cancer Database (NCDB) of patients with confirmed diagnoses of mucoepidermoid carcinoma, acinic cell carcinoma, adenoid cystic carcinoma, adenocarcinoma, or carcinoma ex pleomorphic receiving curative treatment between 2004 and 2014. Univariate and multivariate regression modeling were performed to identify risk factors significantly associated with overall survival (OS). Adjusted survival analyses stratified by treatment and staging were performed with the primary outcome of overall survival (OS) and were further stratified based on histologic subtype.
RESULTS: The final analysis included 7342 patients [3547 men (48.3%) and 3795 women (51.7%); mean age 58.3 years (range 18-90 years)]. Mucoepidermoid carcinoma was the most common histology encountered [n = 2669 (36.4%)]. Unadjusted and adjusted analysis demonstrated improved survival with surgery and radiation therapy (RT) for adenoid cystic (HR = 0.69; p = 0.029), adenocarcinoma (HR = 0.61; p < 0.001), high-grade mucoepidermoid carcinoma (HR = 0.70; p = 0.026), and carcinoma ex pleomorphic (HR = 0.64; p = 0.028), while surgery with chemoradiation therapy (CRT) was associated with worse OS regardless of histologic subtype. The impact of advanced stage on survival varied amongst the histologic subtypes but portended the worst prognosis for patients with adenocarcinoma and carcinoma ex pleomorphic.
CONCLUSIONS: The results of this NCDB review demonstrate unique treatment patterns and survival outcomes for SGC based on major histologic subtype.

Entities:  

Keywords:  Cancer of salivary gland; Head and neck cancer; National Cancer Database; Salivary gland; Treatment outcomes

Mesh:

Year:  2019        PMID: 30649610     DOI: 10.1007/s00405-019-05282-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  31 in total

1.  Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck.

Authors:  William M Mendenhall; Christopher G Morris; Robert J Amdur; John W Werning; Russell W Hinerman; Douglas B Villaret
Journal:  Head Neck       Date:  2004-02       Impact factor: 3.147

2.  Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies.

Authors:  Lewis Rosenberg; Mark Weissler; D Neil Hayes; William Shockley; Adam Zanation; Julian Rosenman; Bhishamjit Chera
Journal:  Head Neck       Date:  2011-08-24       Impact factor: 3.147

3.  Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.

Authors:  Jonathan D Schoenfeld; David J Sher; Charles M Norris; Robert I Haddad; Marshall R Posner; Tracy A Balboni; Roy B Tishler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-13       Impact factor: 7.038

4.  Survival in patients with parotid gland carcinoma - Results of a multi-center study.

Authors:  Keigo Honda; Shinzo Tanaka; Shogo Shinohara; Ryo Asato; Hisanobu Tamaki; Toshiki Maetani; Ichiro Tateya; Morimasa Kitamura; Shinji Takebayashi; Kazuyuki Ichimaru; Yoshiharu Kitani; Yohei Kumabe; Tsuyoshi Kojima; Koji Ushiro; Masanobu Mizuta; Koichiro Yamada; Koichi Omori
Journal:  Am J Otolaryngol       Date:  2017-10-24       Impact factor: 1.808

5.  Outcomes and prognostic factors in modern era management of major salivary gland cancer.

Authors:  Naresh Jegadeesh; Yuan Liu; Roshan S Prabhu; Kelly R Magliocca; David M Marcus; Kristin A Higgins; Jeffrey M Vainshtein; J Trad Wadsworth; Jonathan J Beitler
Journal:  Oral Oncol       Date:  2015-05-29       Impact factor: 5.337

6.  Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.

Authors:  Megan E Daly; Derick H Lau; D Gregory Farwell; Quang Luu; Paul J Donald; Allen M Chen
Journal:  Am J Otolaryngol       Date:  2013-08-15       Impact factor: 1.808

Review 7.  Biology and management of salivary gland cancers.

Authors:  David J Adelstein; Shlomo A Koyfman; Adel K El-Naggar; Ehab Y Hanna
Journal:  Semin Radiat Oncol       Date:  2012-07       Impact factor: 5.934

8.  Salivary gland cancer. A case-control investigation of risk factors.

Authors:  M R Spitz; J J Fueger; H Goepfert; G R Newell
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-10

9.  Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base.

Authors:  Arya Amini; Timothy V Waxweiler; Jeffrey V Brower; Bernard L Jones; Jessica D McDermott; David Raben; Debashis Ghosh; Daniel W Bowles; Sana D Karam
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-11-01       Impact factor: 6.223

10.  Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis.

Authors:  Boban M Erovic; Manish D Shah; Guillem Bruch; Meredith Johnston; U Johnston; John Kim; Brian O'Sullivan; Bayardo Perez-Ordonez; Ilan Weinreb; Eshetu G Atenafu; John R de Almeida; Patrick J Gullane; Dale Brown; Ralph W Gilbert; Jonathan C Irish; David P Goldstein
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-10-29
View more
  4 in total

1.  Overall and cause-specific survival for mucoepidermoid carcinoma of the major salivary glands: Analysis of 2210 patients.

Authors:  Zachary C Taylor; Erin A Kaya; Jeffrey D Bunn; Zachary D Guss; Brian J Mitchell; Robert K Fairbanks; Wayne T Lamoreaux; Aaron E Wagner; Ben J Peressini; Christopher M Lee
Journal:  World J Clin Oncol       Date:  2020-12-24

2.  Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Authors:  Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro
Journal:  Strahlenther Onkol       Date:  2019-07-26       Impact factor: 3.621

3.  Clinicopathologic Features and Survival Trends for Acinic Cell Carcinoma of the Major Salivary Glands: A Surveillance, Epidemiology, and End Results Population Analysis.

Authors:  Erin A Kaya; Zachary C Taylor; Brian J Mitchell; Zachary D Guss; Jeffrey D Bunn; Robert K Fairbanks; Wayne T Lamoreaux; Aaron E Wagner; Ben J Peressini; Christopher M Lee
Journal:  World J Oncol       Date:  2020-10-15

4.  Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period.

Authors:  Michał Żurek; Kamil Jasak; Karolina Jaros; Piotr Daniel; Kazimierz Niemczyk; Anna Rzepakowska
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.